Boston, January 08, 2024, The Europe Today: On the inaugural day of a prominent U.S. healthcare conference, Johnson & Johnson and Merck revealed their intentions to acquire cancer therapy developers, signaling the commencement of what industry insiders anticipate to be a robust year for deals following a favorable conclusion to 2023.
The disclosed transactions on Monday collectively held an equity value surpassing $6 billion, featuring notable engagements such as medical device manufacturer Boston Scientific’s acquisition of Axonics Inc.
This announcement follows a trend, with data from LSEG Deals Intelligence indicating that the previous month saw U.S.-listed biotech deals amounting to approximately $25 billion. The strategic moves within the healthcare sector underscore a continued momentum in deal-making, reflecting the industry’s commitment to advancing innovative solutions and therapeutic advancements.
